{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T10:05:50Z","timestamp":1789034750173,"version":"build-2803163510"},"reference-count":14,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,11,30]],"date-time":"2021-11-30T00:00:00Z","timestamp":1638230400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> Atrial arrhythmia (AA) is common among patients with cardiac amyloidosis (CA), who have an increased risk of intracardiac thrombus. The aim of this study was to explore the prognostic impact of vitamin K-antagonists (VKA) and direct oral anticoagulants (DOAC) in patients with CA.<\/jats:p><jats:p><jats:bold>Methods and Results:<\/jats:bold> 273 patients with CA and history of AA with long term anticoagulation\u221269 (25%) light chain amyloidosis (AL), 179 (66%) wild-type transthyretin amyloidosis (ATTRwt) and 25 (9%) variant transthyretin amyloidosis (ATTRv)\u2013were retrospectively included between January 2012 and July 2020. 147 (54%) and 126 (46%) patients received VKA and DOAC, respectively. Patient receiving VKA were more likely to have AL with renal dysfunction, higher NT-proBNP and troponin levels. Patients with ATTRwt were more likely to receive DOAC therapy. There were more bleeding complications among patients with VKA (20 versus 10%; <jats:italic>P<\/jats:italic> = 0.013) but no difference for stroke events (4 vs. 2%; <jats:italic>P<\/jats:italic> = 0.223), as compared to patients with DOAC. A total of 124 (45%) patients met the primary endpoint of all-cause mortality: 96 (65%) and 28 (22%) among patients with VKAs and DOACs, respectively (<jats:italic>P<\/jats:italic> &amp;lt; 0.001). After multivariate analysis including age and renal function, VKA was no longer associated with all-cause mortality.<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> Among patients with CA and history of AA receiving oral anticoagulant, DOACs appear to be at least as effective and safe as VKAs.<\/jats:p>","DOI":"10.3389\/fcvm.2021.742428","type":"journal-article","created":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T20:16:41Z","timestamp":1638389801000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":24,"title":["New Oral Anticoagulants vs. Vitamin K Antagonists Among Patients With Cardiac Amyloidosis: Prognostic Impact"],"prefix":"10.3389","volume":"8","author":[{"given":"Eve","family":"Cariou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Sanchis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khail\u00e8ne","family":"Rguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginie","family":"Blanchard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Cazalbou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pauline","family":"Fournier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Huart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murielle","family":"Roussel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Cintas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Galinier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Didier","family":"Carri\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Maury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoan","family":"Lavie-Badie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Lairez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,11,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2420","DOI":"10.1161\/CIRCULATIONAHA.107.697763","article-title":"Intracardiac thrombosis and embolism in patients with cardiac amyloidosis","volume":"116","author":"Feng","year":"2007","journal-title":"Circulation."},{"key":"B2","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1016\/j.jacc.2018.10.080","article-title":"Cardiac amyloidosis and the risks of cardioversion","volume":"73","author":"Anderson","year":"2019","journal-title":"J Am Coll Cardiol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"2893","DOI":"10.1093\/eurheartj\/ehw210","article-title":"2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS","volume":"37","author":"Kirchhof","year":"2016","journal-title":"Eur Heart J."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1016\/j.jacep.2019.10.013","article-title":"No association between CHADS-VASc score and left atrial appendage thrombus in patients with transthyretin amyloidosis","volume":"5","author":"Donnellan","year":"2019","journal-title":"JACC Clin Electrophysiol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","article-title":"2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)","volume":"42","author":"Hindricks","year":"2021","journal-title":"Eur Heart J."},{"key":"B6","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1080\/13506129.2019.1620724","article-title":"Atrial fibrillation and subtype of atrial fibrillation in cardiac amyloidosis: clinical and echocardiographic features, impact on mortality","volume":"26","author":"Sanchis","year":"2019","journal-title":"Amyloid Int J Exp Clin Investig."},{"key":"B7","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1111\/j.1538-7836.2010.03975.x","article-title":"ISTH\/SSC bleeding assessment tool: a standardized questionnaire and a proposal for a new bleeding score for inherited bleeding disorders","volume":"8","author":"Rodeghiero","year":"2010","journal-title":"J Thromb Haemost."},{"key":"B8","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N Engl J Med."},{"key":"B9","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1080\/13506129.2020.1810010","article-title":"Anticoagulation with warfarin compared to novel oral anticoagulants for atrial fibrillation in adults with transthyretin cardiac amyloidosis: comparison of thromboembolic events and major bleeding","volume":"28","author":"Mitrani","year":"2020","journal-title":"Amyloid Int J Exp Clin Investig."},{"key":"B10","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1002\/ehf2.12308","article-title":"Features of atrial fibrillation in wild-type transthyretin cardiac amyloidosis: a systematic review and clinical experience","volume":"5","author":"Mints","year":"2018","journal-title":"ESC Hear Fail."},{"key":"B11","doi-asserted-by":"publisher","first-page":"147","DOI":"10.3109\/13506129.2015.1028616","article-title":"Atrial fibrillation in amyloidotic cardiomyopathy: prevalence, incidence, risk factors and prognostic role","volume":"22","author":"Longhi","year":"2015","journal-title":"Amyloid Int J Exp Clin Investig."},{"key":"B12","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.jacc.2018.10.079","article-title":"Direct current cardioversion of atrial arrhythmias in adults with cardiac amyloidosis","volume":"73","author":"El-Am","year":"2019","journal-title":"J Am Coll Cardiol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1038\/s41379-019-0407-5","article-title":"Amyloidosis in surgically resected atrial appendages: a study of 345 consecutive cases with clinical implications","volume":"33","author":"Fayyaz","year":"2020","journal-title":"Mod Pathol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"2799","DOI":"10.1093\/eurheartj\/ehx589","article-title":"A new staging system for cardiac transthyretin amyloidosis","volume":"39","author":"Gillmore","year":"2018","journal-title":"Eur Heart J."}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2021.742428\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T20:16:43Z","timestamp":1638389803000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2021.742428\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,30]]},"references-count":14,"alternative-id":["10.3389\/fcvm.2021.742428"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2021.742428","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,30]]},"article-number":"742428"}}